Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma

Journal of Translational Medicine

Luigi Aloj¹  Corradina Caracò¹  Paolo A Ascierto²  Gerardo Botti⁴  Gianluca Di Monta³  Stefano Mori³  Corrado Caracò³  Nicola Mozzillo³ 

[1] Department of Nuclear Medicine, National Cancer Institute, Via Mariano Semmola, Naples, Italy;Medical Oncology and Innovative Therapies Unit, National Cancer Institute, Via Mariano Semmola, Naples, Italy;Department of Surgery “Melanoma - Soft Tissues - Head & Neck - Skin Cancers”, National Cancer Institute, Via Mariano Semmola, Naples, Italy;Department of Pathology, National Cancer Institute, Via Mariano Semmola, Naples, Italy

关键词: Adjuvant treatment;    Melanoma;    Electrochemotherapy;   

Others  :  1205950
DOI  :  10.1186/1479-5876-10-131

 received in 2012-03-01, accepted in 2012-06-22,  发布年份 2012

【 摘 要 】

Background

Approximately 200,000 new cases of melanoma are diagnosed worldwide each year. Skin metastases are a frequent event, occurring in 18.2% of cases. This can be distressing for the patient, as the number and size of cutaneous lesions increases, often worsened by ulceration, bleeding and pain. Electrochemotherapy (ECT) is a local modality for the treatment of cutaneous or subcutaneous tumors that allows delivery of low- and non-permeant drugs into cells. ECT has been used in palliative management of metastatic melanoma to improve patients’ quality of life. This is, to our knowledge, the first application of ECT as neoadjuvant treatment of metastatic subcutaneous melanoma.

Methods and results

A 44-year-old Caucasian woman underwent extensive surgical resection of a melanoma, with a Breslow thickness of 1.5 mm, located on the right side of her scalp. No further treatment was given and the woman remained well until she came to our attention with a large nodule in her right cheek. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) was performed for staging and treatment monitoring. Baseline FDG PET/CT showed the lesion in the cheek to have a maximal standardized uptake value (SUVmax) of 19.5 with no evidence of further disease spread. Fine needle aspiration cytology confirmed the presence of metastatic melanoma. The patient underwent two sessions of ECT with intravenous injections of bleomycin using a Cliniporator^TM as neoadjuvant treatment permitting conservative surgery three months later.

Follow-up PET/CT three months after the first ECT treatment showed a marked decrease in SUVmax to 5. Further monitoring was performed through monthly PET/CT studies. Multiple cytology examinations showed necrotic tissue. Conservative surgery was carried out three months after the second ECT. Reconstruction was easily achieved through a rotation flap. Pathological examination of the specimen showed necrotic tissue without residual melanoma. One year after the last ECT treatment, the patient was disease-free as determined by contrast-enhanced CT and PET/-CT scans with a good functional and aesthetic result.

Conclusions

ECT represents a safe and effective therapeutic approach that is associated with clear benefits in terms of quality of life (minimal discomfort, mild post-treatment pain and short duration of hospital stay) and may, in the neoadjuvant setting as reported here, offer the option of more conservative surgery and an improved cosmetic effect with complete local tumor control.

【 授权许可】

   
2012 Mozzillo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organization, International Agency for Research on Cancer: GLOBOCAN 2008. Cancer incidence, mortality and prevalence worldwide in 2008. , ; 2012. http://globocan.iarc.fr webcite)
• [2]Gimbel MI, Delman KA, Zager JS: Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008, 15:225-232.
• [3]Savoia P, Fava P, Nardò T, Osella-Abate S, Quaglino P, Bernengo MG: Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 2009, 19:321-326.
• [4]Mir L: Bases and rationale of the electrochemotherapy. Eur J Cancer 2006, Suppl 4:38-44.
• [5]Marty M, Sersa G, Garbay JR, et al.: Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases. Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer 2006, Suppl 4:3-13.
• [6]Quaglino P, Mortera C, Osella-Abate S, et al.: Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008, 15:2215-2222.
• [7]Campana LG, Mocellin S, Basso M, et al.: Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009, 16:191-199.
• [8]Kubota Y, Tomita Y, Tsukigi M, Kurachi H, Motoyama T, Mir LM: A case of perineal malignant melanoma successfully treated with electrochemotherapy. Melanoma Res 2005, 15:133-134.
• [9]Kaehler KC, Egberts F, Hauschild A: Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg 2010, 36:1200-1202.
• [10]Orlowski S, Belehradek J, Paoletti C, Mir LM: Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988, 37:4727-4733.
• [11]Gehl J, Geertsen PF: Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy. Eur J Cancer 2006, Suppl 4:35-37.
• [12]Jarm T, Cemazar M, Miklavcic D, Sersa G: Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010, 10:729-746.
• [13]Mir LM, Glass LF, Sersa G, et al.: Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998, 77:2336-2342.
• [14]Heller R, Jaroszeski MJ, Reintgen DS, et al.: Treatment of cutaneous and subcutaneous tumors with electrcochemotherapy using intralesional bleomycin. Cancer 1998, 83:148-157.
• [15]Testori A, Tosti G, Martinoli C, et al.: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: A novel therapeutic approach. Dermatol Ther 2010, 23:651-661.
• [16]Sersa G, Cufer T, Paulin SM, Cemazar M: Snoj M. Electrochemotherapy of chest wall breast cancer recurrence, Cancer Treat Rev; 2011.
• [17]Curatolo P, Quaglino P, Marenco F, Mancini M, Nardò T, Mortera C, Rotunno R, Calvieri S, Bernengo : Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012, 19:192-198.
• [18]Landström FJ, Nilsson CO, Reizenstein JA, Nordqvist K, Adamsson GB, Löfgren AL: Electroporation therapy for T1 and T2 oral tongue cancer. Acta Otolaryngol 2011, 131:660-664.
• [19]Kis E, Oláh J, Ócsai H, Baltas E, Gyulai R, Kemény L, Horvath AR: Electrochemotherapy of cutaneous metastases of melanoma–a case series study and systematic review of the evidence. Dermatol Surg 2011, 37:816-824.
• [20]Mir LM, Belehradek M, Domenge C, et al.: Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Acad Sci III 1991, 313:613-618.
• [21]Matthiessen LW, Chalmers RL, Sainsbury DC, et al.: Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011, 50:621-629.
• [22]Testori A, Faries MB, Thompson JF, et al.: Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011, 104:391-396.
• [23]Snoj M, Rudolf Z, Paulin-Kosir SM, et al.: Long lasting complete response in melanoma treated by electrochemotherapy. Eur J Cancer 2006, Suppl 4:26-28.
• [24]Snoj M, Rudolf Z, Cemazar M, et al.: Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005, 16:345-348.
• [25]Shimizu T, Nikaido T, Gomyo H, et al.: Electrochemotherapy of digital chondrosarcoma. J Orthop Sci 2003, 8:248-251.